Dr. Gandara Discusses Third-Generation EGFR TKIs

David R. Gandara, MD
Published: Monday, Aug 11, 2014

David R. Gandara, MD, Professor of Medicine, Division of Hematology and Oncology, Director, Thoracic Oncology Program, Associate Director, Clinical Research, UC Davis Comprehensive Cancer Center, discusses examining third-generation EGFR TKIs in lung cancer.

Gandara says third-generation EGFR TKIs are exciting. CO-1686 and AZD9291 are two agents that are being looked at in several trials in different settings for patients that have EGFR-mutated lung cancer.

AstraZeneca, the maker of AZD9291, has recently signed an agreement with the National Cancer Institute to conduct study through the cooperative group, Gandara says. Gandara is the co-leader of this project team and is hopeful for proposals to incorporate AZD9291 in combination.

David R. Gandara, MD, Professor of Medicine, Division of Hematology and Oncology, Director, Thoracic Oncology Program, Associate Director, Clinical Research, UC Davis Comprehensive Cancer Center, discusses examining third-generation EGFR TKIs in lung cancer.

Gandara says third-generation EGFR TKIs are exciting. CO-1686 and AZD9291 are two agents that are being looked at in several trials in different settings for patients that have EGFR-mutated lung cancer.

AstraZeneca, the maker of AZD9291, has recently signed an agreement with the National Cancer Institute to conduct study through the cooperative group, Gandara says. Gandara is the co-leader of this project team and is hopeful for proposals to incorporate AZD9291 in combination.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
Publication Bottom Border
Border Publication
x